Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a ...

The global COPD therapeutics market is on a robust growth trajectory, having achieved a market valuation of USD 12,144.1 million in 2023, and is projected to reach USD 20,035.5 million by 2033, ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

Several male enhancement dietary supplements have been recalled due to undeclared and potentially harmful ingredients being ...

EVP Susan Galbraith noted confidence in the TROP2 biomarker strategy and highlighted the oral PCSK9 inhibitor's distinct small molecule profile. Analysts displayed cautious optimism regarding ...

announces newly published data supporting the potential of its Inflammasome ASC Inhibitor IC 100 to slow the progression of Parkinson’s disease.

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced ...

Roflumilast cream 0.3% is a once-daily phosphodiesterase-4 inhibitor that was recently approved by the FDA ... Instead of a placebo firm should use emollients 5. Specific lab tests shall be included ...

suggest that the drug apremilast -- a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation -- could be repurposed as a dual-acting therapy for AUD ...